A5009264396- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Sarcoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Breast Cancer Treatment Studies
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Angiogenesis and VEGF in Cancer
- Metastasis and carcinoma case studies
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Occupational and environmental lung diseases
- Advanced Biosensing Techniques and Applications
- Endometriosis Research and Treatment
- Estrogen and related hormone effects
- Colorectal and Anal Carcinomas
- Cancer Diagnosis and Treatment
- Testicular diseases and treatments
Saitama Medical University
2014-2025
Saitama International Medical Center
2022-2025
Jikei University School of Medicine
2025
National Cancer Center Hospital East
2015-2024
National Cancer Center
2018-2024
National Cancer Centre Japan
2023
Chiang Mai University
2023
Mackay Memorial Hospital
2023
Tokyo National Hospital
2016-2022
Yazaki (United States)
2020
Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR
PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients uterine carcinosarcoma (UCS) expressing HER2. PATIENTS AND METHODS Patients recurrent UCS HER2 immunohistochemistry scores ≥1+ previously treated chemotherapy were included. assigned to HER2-high (immunohistochemistry score ≥2+; n = 22) or low 1+; 10) groups for primary exploratory...
Clear cell sarcoma (CCS) and alveolar soft part (ASPS) are rare, standard systemic therapy is not established except for sunitinib in ASPS. It known that CCS ASPS have a common biological feature of melanoma Xp11.2/TFE3 translocation renal carcinoma, immune-checkpoint inhibitors (ICIs) effective these tumors. The authors conducted phase 2 trial to evaluate the efficacy safety nivolumab
PIK 3 CA mutations are common activating associated with breast cancer (occurring in 20–30% of all cases) and potent predictive markers for responses to PI 3K inhibitors. Thus, it is important develop sensitive methods detect these mutations. We established a novel detection method using quenching probe ( QP ) system identify mutations, DNA from 309 tissues. In developmental cohort, we determined the optimal threshold human tumor 119 freshly frozen samples. found 96% concordance rate between...
Abstract Purpose: We assessed the intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan, T-DXd (known as DS-8201a), a novel HER2-targeted antibody–drug conjugate, using phosphor-integrated dots (PID)-imaging analysis to elucidate its pharmacologic mechanism. Experimental Design: used two mouse xenograft models administered at concentration 4 mg/kg: (i) heterogeneous model in which HER2-positive and HER2-negative cell lines were mixed, (ii) homogeneous both types transplanted...
Abstract Background: Endometrial cancer (EC) represents a significant health burden globally, particularly in postmenopausal women. Current treatment options for advanced-stage EC remain limited, emphasizing the need novel therapeutic strategies. This study aimed to investigate farletuzumab ecteribulin (FZEC), an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), as potential new agent using tumor models. Methods:We utilized panel of 24 patient-derived xenograft (PDX)...
Abstract Purpose: Uterine carcinosarcoma (UCS), a subtype of endometrial carcinoma, is rare and aggressive cancer with poor prognosis. High clinical efficacy trastuzumab deruxtecan (T-DXd) in HER2-expressing UCS was recently reported phase II trial (STATICE trial). We performed co-clinical study T-DXd using patient-derived xenograft (PDX) models participants the STATICE trial. Experimental Design: Tumor specimens were resected during primary surgery or biopsied at recurrence from patients...
Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene in non-small-cell lung cancer and has also been identified other types of tumors. However, there limited evidence on the clinical response to ALK tyrosine inhibitors (TKIs), such as alectinib crizotinib, rare tumors with fusion. We evaluated therapeutic effect ALK-TKIs ALK-rearranged tumors.Between April 2012 2019, outcomes characteristics patients nonlung solid who received (alectinib and/or crizotinib) outside...
Triple-negative breast cancer (TNBC) is negative for hormone receptors and human epidermal growth factor receptor 2 (HER2). In stage I TNBC, adjuvant therapy or follow-up are performed according to risk factors, but clinical trial data scarce. recent years, it has been reported that HER2-low cases (1+/2+ in situ hybridization negative) have different prognoses than HER2-0 cases. However, the of recurrence factors this population TNBC not yet investigated.Herein, out 174 patients with who...
Abstract Prognostic value of hematologic indices and their association with the tumor microenvironment (TME) remain unclear in advanced soft tissue sarcoma (STS). We aimed to evaluate prognostic correlation TME status STS treated first-line doxorubicin (DXR) therapy. Clinical data three hematological indices, including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte were collected from 149 patients STS. The was pathologically examined by CD3, CD68,...
Adding bevacizumab to chemotherapy for recurrent, persistent or metastatic cervical cancer significantly improved overall survival (primary endpoint), progression-free and response rate in the randomized Phase III GOG-0240 trial. However, data bevacizumab-containing therapy are scarce Japanese patients with advanced cancer.The primary objective of single-arm multicenter II JO29569 study was evaluate tolerability paclitaxel (135 mg/m2 over 24 h 175 3 h), cisplatin (50 mg/m2) (15 mg/kg),...